VanEck announced today the following 2025 annual distributions per share for its VanEck ® equity exchange-traded funds. Distributions Per Share for the...
/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.
Vertex Pharmaceuticals has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.
/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Bio-Techne has underperformed the broader market this year, but Wall Street analysts are optimistic about the stock’s prospects.
/Biogen%20Inc%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.
/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.
/AMGEN%20Inc_%20logo%20on%20website-by%20Jimmy%20Tudeschi%20via%20Shutterstock.jpg)
Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.
Moderna has outperformed many of its peers and the broader market YTD, but Wall Street analysts are cautiously optimistic about the stock's prospects.
Amgen has outperformed the broader market and many of its peers over the past year, but Wall Street analysts believe it has limited upside left.